The other side of TNF-targeted therapy of patients with rheumatoid arthritis.
Abe
T
T
Department of Internal Medicine, Saitama Medical Center/School, Kamoda, Kawagoe-shi, Saitama 350-8550, Japan. tohruabe@saitama-med.ac.jp
Takeuchi
T
T
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000069285:Infliximab; D007564:Japan / Q000453:epidemiology; D008727:Methotrexate / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate